As the energy factory for the cell, the mitochondrion, through its role of
adenosine triphosphate production by oxidative phosphorylation, can be regarded as the guardian of well regulated cellular metabolism; the integrity of mitochondrial functions, however, is particularly vulnerable in
cancer due to the lack of superstructures such as
histone and lamina folds to protect the mitochondrial genome from unintended exposure, which consequently elevates risks of mutation. In
cancer, mechanisms responsible for enforcing quality control surveillance for identifying and eliminating defective mitochondria are often poorly regulated, and certain uneliminated
mitochondrial DNA (
mtDNA) mutations and polymorphisms can be advantageous for the proliferation, progression, and
metastasis of
tumor cells. Such pathogenic
mtDNA aberrations are likely to increase and occasionally be homoplasmic in
cancer cells and, intriguingly, in normal cells in the proximity of tumor microenvironments as well. Distinct characteristics of these abnormalities in
mtDNA may provide a new path for
cancer therapy. Here we discuss a promising novel therapeutic strategy, using the sequence-specific properties of
pyrrole-
imidazole polyamide-
triphenylphosphonium conjugates, against
cancer for clearing abnormal
mtDNA by reactivating mitochondrial quality control surveillance.